Publications, posters & presentations

Publications, posters & presentations -
our significant research

Filter
Research Area
Technology
Resource type
Category
110 results found
Mar 20, 2023
Publication
Novavax led
Pre-print
COVID-19, Matrix-M™ adjuvant
Immunogenicity and Safety of NVX-CoV2373 as a Homologous or Heterologous Booster: A Phase 3 Randomized Clinical Trial in Adults
Raisera, Fritz, Davisb, Matthew, Adelglassc, Jeffrey, et al.
Mar 19, 2023
Publication
Novavax led
Pre-print
COVID-19, Matrix-M™ adjuvant
NVX-CoV2373 Vaccine Efficacy Against Hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial
Marchese, Anthony M., Zhou, Xiang, Kinol, John, et al.
Feb 28, 2023
Publication
Collaborative
Nature Communications
COVID-19, Matrix-M™ adjuvant
Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants
Logue, James, Johnson, Robert M., Patel, Nita, et al.
Jan 25, 2023
Publication
Novavax led
Scientific Reports
COVID-19, Matrix-M™ adjuvant
Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373
Alves, Katia, Plested, Joyce S., Galbiati, Shirley, et al.
Jan 21, 2023
Publication
Collaborative
Scientific Reports
COVID-19, Matrix-M™ adjuvant
Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
Bhiman, Jinal N. , Richardson, Simone I., Lambson, Bronwen E., et al.
Nov 2, 2022
Publication
Novavax led
Vaccines
COVID-19
With established safe and effective use, protein vaccines offer another choice against COVID-19
Marchese, Anthony M. , Beyhaghi, Hadi , Orenstein, Walter A.
Oct 24, 2022
Presentation
Novavax included/third party
COVID-19, Matrix-M™ adjuvant
Safety and immunogenicity of a booster dose of Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) in adults from the PREVENT-19 Trial in the United States
Áñez1, Germán, Dunkle, Lisa M. , Gay, Cynthia L. , et al.
Oct 13, 2022
Presentation
Novavax led
COVID-19, Seasonal influenza
Update on Novavax Investigational Influenza vaccine and COVID-19-Influenza Combination Vaccine development
Oct 13, 2022
Presentation
Novavax led
COVID-19, Matrix-M™ adjuvant
Paving the way for Protein: Novavax’s COVID-19 Vaccine as a Booster and Variant-adapted
Aug 10, 2022
Publication
Novavax led
The Lancet Infectious Diseases
COVID-19
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
Mallory, Raburn M., Formica, Neil, Pfeiffer, Susan, et al.